University of Pennsylvania Researchers Receive Penn One Health Award for Research Initiatives in Canine Osteosarcoma With Advaxis, Inc.'s ADXS-cHER2 Immunotherapy
3/11/2013 10:52:37 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Dr. Nicola Mason, lead investigator of the Penn canine study, and Dr. Yvonne Paterson, scientific founder of Advaxis, have received the inaugural University of Pennsylvania One Health Award for their research of Advaxis’ proprietary immunotherapy, ADXS-cHER2, for the treatment of canine osteosarcoma. The One Health Award, a new award for excellence in promoting One Health initiatives and inter-professional education, was established this year by the deans of the four health schools at Penn – Medicine, Nursing, Veterinary Medicine, and Dental Medicine. The award recognizes exemplary contributions toward expanding interdisciplinary education and improving health care.
comments powered by